Wall Street Zen Downgrades Tvardi Therapeutics (NASDAQ:TVRD) to Sell

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Friday.

Other equities research analysts have also recently issued research reports about the company. Piper Sandler cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Raymond James Financial downgraded Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Finally, Barclays set a $5.00 price target on Tvardi Therapeutics and gave the company an “equal weight” rating in a report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $55.50.

Tvardi Therapeutics Stock Performance

TVRD opened at $4.69 on Friday. The business’s 50-day simple moving average is $4.21 and its 200-day simple moving average is $16.78. The stock has a market capitalization of $43.99 million, a P/E ratio of -0.49 and a beta of 0.09. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the second quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at $43,000. Headlands Technologies LLC bought a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $80,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics in the second quarter valued at about $92,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Tvardi Therapeutics during the third quarter worth $318,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.